Jagsonpal Pharmaceuticals Limited has informed the Exchange about Investor Presentation
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals reported H1FY26 revenue of ₹1,501 Mn, up 10.2% YoY, with PAT surging 39.2% to ₹234 Mn. Q2FY26 revenue was largely flat at ₹745 Mn (down 0.3% YoY) due to temporary moderation from GST 2.0 transition, though PAT grew 9.7% to ₹126 Mn with margins expanding 154 bps to 16.9%. Operating EBITDA margins slipped marginally to 24.3% in Q2 (-39 bps) and 22.5% in H1 (-31 bps), as the company passed on full GST benefits to consumers. The company maintains a strong cash balance of ₹1,604 Mn, paid out a 125% dividend (₹166 Mn), and appointed a new COO (Amrut Medhekar) and CFO (Nirav Vora). The investor presentation highlighted an asset-light model and signaled intent for inorganic growth through brand and business acquisitions.
Positive for shareholders — robust H1 PAT growth, expanding profit margins, strong cash reserves, and higher dividend payouts signal financial health. Near-term Q2 softness from GST transition is already explained, and management expects growth to accelerate in H2. Watch for execution of the inorganic growth strategy and any acquisition announcements.